Neonatal TPN Starter Bag, Amino Acids (Trophamine) 4.5%/Dextrose 10% with HEPARIN, packaged in 25...
FDA Drug Recall #D-0700-2023 — Class II — April 28, 2023
Recall Summary
| Recall Number | D-0700-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 28, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Central Admixture Pharmacy Services, Inc. |
| Location | Allentown, PA |
| Product Type | Drugs |
| Quantity | 175 bags |
Product Description
Neonatal TPN Starter Bag, Amino Acids (Trophamine) 4.5%/Dextrose 10% with HEPARIN, packaged in 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., Lehigh Valley, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-0432-1.
Reason for Recall
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Distribution Pattern
Nationwide in the USA.
Lot / Code Information
Lot # 37-894962, Exp 05/01/2023; 37-898285, Exp 05/14/2023
Other Recalls from Central Admixture Pharmacy Services, ...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0272-2025 | Class I | PHENYLephrine added to 0.9% sodium chloride, 40... | Feb 20, 2025 |
| D-1117-2023 | Class II | Neonatal TPN Starter Bag, Amino Acids (trophami... | Aug 17, 2023 |
| D-1130-2023 | Class II | EPINEPHrine added to 0.9% sodium chloride, 4mg/... | Aug 17, 2023 |
| D-1111-2023 | Class II | Cardioplegia Solution, low K, Maintenance 4:1 P... | Aug 17, 2023 |
| D-1138-2023 | Class II | dilTIAZem 125mg/125mL (1 mg/mL), added to dextr... | Aug 17, 2023 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.